Financials
Financial year 2025
PHARMA AND CCS CONSULTING from Chaudfontaine, company number BE0772858683, closed financial year 2025 with a result of € 94,244 after tax. For that financial year PHARMA AND CCS CONSULTING recorded a gross margin of € 148,725 and equity of € 412,706. Compared with financial year 2024, the result moved from € 73,736 to € 94,244. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 412,706
▲ 29% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 94,244
▲ 28% vs 2024
Profit after tax over the fiscal year.
€ 433,790
▲ 43% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 400 paid out
0 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 5,440
▼ 65% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,680
▲ € 3,567 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 33,245
▲ 34% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 287,210 | € 84,005 | € 117,820 | € 148,725 | ▲ 26% |
| Profit after taxes | € 189,636 | € 50,490 | € 73,736 | € 94,244 | ▲ 28% |
| Equity | € 194,636 | € 245,126 | € 318,863 | € 412,706 | ▲ 29% |
| Total debts | € 35,327 | € 18,343 | € 28,856 | € 43,548 | ▲ 51% |
| Cash | € 163,554 | € 232,089 | € 302,476 | € 433,790 | ▲ 43% |
| Retained profit | € 189,636 | € 240,126 | € 313,863 | € 407,706 | ▲ 30% |
| Dividend | € 0 | € 0 | € 0 | € 400 | |
| Balance sheet total | € 229,963 | € 263,470 | € 347,718 | € 456,254 | ▲ 31% |
Key figures of PHARMA AND CCS CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA AND CCS CONSULTING?
What happened at PHARMA AND CCS CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 94,244 (▲ 28% vs 2024). Source: NBB ↗
- New establishment in Chaudfontaine. KBO
- Brigitte JEANGETTE became a director. NBB
- Eric CLAESSENS became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 189,636 profit in 2022 to € 94,244 profit in 2025.
Paid € 180,629 in corporate taxes since 2022.
Best year ever: 2022, with € 189,636 profit.
Paid out € 400 in dividends to the owners in total.
A new publication or filing at PHARMA AND CCS CONSULTING? We notify you, reason included.
Follow PHARMA AND CCS CONSULTINGDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMA AND CCS CONSULTING are Brigitte JEANGETTE and Eric CLAESSENS.
Directors
According to the 2025 annual accounts
Brigitte JEANGETTE
Director
since 2021
Eric CLAESSENS
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Rue Albert et Louis Curvers 50
4053 Chaudfontaine
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0772.858.683
- VAT number
- BE 0772.858.683
- Registered office
- Rue Albert et Louis Curvers 50, 4053 Chaudfontaine
- Names & denominations
- PHARMA AND CCS CONSULTING
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 August 2021
- Peppol
- Active · Active since 9 Dec 2025
- Contact
- [email protected]
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten op het gebied van voeding
Overige technische testen en toetsen
Overige vormen van onderwijs
Overige zakelijke dienstverlening, neg
Overige menselijke gezondheidszorg, n.e.g.